China Approves Imports of J&J’s Tremfya

China’s National Medical Products Administration has cleared Johnson and Johnson’s Tremfya (guselkumab) for importation.

The agency approved the drug for treatment of moderate-to-severe plaque psoriasis in adults who are suitable for systemic therapy.

J&J is positioning Tremfya as an alternative to Novartis’ Cosentyx (secukinumab), one of the top selling psoriasis treatments.